Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.42 | 0.35 | -0.43 | -1.97 |
| FCF Yield | 3.81% | 2.32% | 1.77% | 0.92% |
| EV / EBITDA | 66.30 | 24.99 | 35.35 | 35.31 |
| Quality | ||||
| ROIC | 1.39% | 2.30% | 2.13% | 2.76% |
| Gross Margin | 51.42% | 49.59% | 49.99% | 46.45% |
| Cash Conversion Ratio | 3.03 | 1.15 | 1.39 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.35% | 10.02% | 11.98% | 13.50% |
| Free Cash Flow Growth | 88.74% | 2.65% | 46.75% | -64.02% |
| Safety | ||||
| Net Debt / EBITDA | 17.39 | 7.56 | 8.97 | 7.67 |
| Interest Coverage | 4.03 | 6.72 | 5.93 | 7.03 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.46 | 0.46 | 0.65 |
| Cash Conversion Cycle | 209.28 | 222.84 | 216.75 | 177.65 |